DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council.

The meeting will be open to the public online as indicated below, with attendance limited to online participation only. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Arthritis and Musculoskeletal and Skin Diseases Advisory Council.

Date: September 1, 2020.

Open: 10:00 AM to 12:45 PM.

Agenda: To discuss program policies and issues.

Place: National Institutes of Health
Bethesda, MD
(Virtual Meeting)

Virtual Access: The meeting will be videocast and can be accessed from the NIH Videocast http://videocast.nih.gov Please note, the link to the videocast meeting will be posted within a week of the meeting date. Any member of the public may submit written comments no later than 15 days after the meeting.

Closed: 2:00 PM – 3:30 PM.

Agenda: To Review and Evaluate Grant Applications.

Contact Person: Melinda Nelson
Acting Director
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Grants Management Branch
45 Center Drive, Natcher Building, Room 5A49
Bethesda, MD 20892
Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

**Dated:** August 18, 2020.

**Miguelina Perez,**  
*Program Analyst,*  
*Office of Federal Advisory Committee Policy.*

[FR Doc. 2020-18441 Filed: 8/21/2020 8:45 am; Publication Date: 8/24/2020]